BTG revises annual revenue forecast higher

Healthcare company BTG said on Thursday it has delivered robust full-year results driven by sales across its speciality pharmaceuticals and licensing and biotechnology divisions.

Healthcare company BTG said on Thursday it has delivered robust full-year results driven by sales across its speciality pharmaceuticals and licensing and biotechnology divisions.

The group expects revenue of £230m for the year ended March 31st 2013, according to a trading update ahead of the annual financial statement.

Royalties from products including prostate cancer treatment Zytiga have helped boost results since January when revenue was pegged between £205m to £215m.

Results were also bolstered by favourable exchange rate movements and an agreement of a final sum relating to the discontinued CytoFab programme for treatment of severe sepsis.

Second stage trials of CytoFab - an experimental medicine owned by BTG but licensed to AstraZeneca - were ceased last August after the drug failed significantly to aid patients.

On the flip side, the company successfully completed the US phase two trial programme for Varisolve and submission of a new drug application seeking approval of PEM as a comprehensive treatment to improve the symptoms and appearance of varicose veins.

BTG also in the US launched Voraxaze (glucarpidase), a treatment for life-threatening toxicity in patients with renal impairment who are receiving high-dose methotrexate therapy.

Progress was made towards the submission of humanitarian device exemption applications in the US for the novel pre-loaded Precision Bead and Paragon Bead for use in uveal melanoma liver metastases and intrahepatic cholangiocarcinoma respectively.

"There has been good progress across the business," Chief Executive Louise Makin said.

"Our specialty pharmaceuticals and licensing and biotechnology businesses continue to give us a strong financial underpin. We have a clear strategy to create further value from the cash we are generating, by conducting studies to expand the uses of our interventional oncology products and through the acquisition of complementary products."

RD

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Why investors should be “cautiously bullish” for 2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

Will a second wave of Covid lead to another stockmarket crash?
Stockmarkets

Will a second wave of Covid lead to another stockmarket crash?

Can we expect to see another lockdown like in March, and what will that mean for your money? John Stepek explains.
18 Sep 2020
Here’s why you really should own at least some bitcoin
Bitcoin

Here’s why you really should own at least some bitcoin

While bitcoin is having a quiet year – at least in relative terms – its potential to become the default cash system for the internet is undiminished, …
16 Sep 2020
James Ferguson: How bad data is driving fear of a second wave of Covid-19
UK Economy

James Ferguson: How bad data is driving fear of a second wave of Covid-19

Merryn and John talk to MoneyWeek regular James Ferguson about the rise in infections in coronavirus and what the data is really telling us.
17 Sep 2020